Tumor Angiogenesis Basic Mechanisms and Cancer Therapy /
Preface Tumor development and progression occur as a result of cumulative acquisition of genetic alterations affecting oncogenes and tumor suppressor genes. As a consequence of these alterations the arising tumor gains some fatal properties such as increased cell proliferation and decreased apoptosi...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | , |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Berlin, Heidelberg :
Springer Berlin Heidelberg,
2008.
|
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Historical Overview
- Tumor Angiogenesis: from Bench to Bedside
- Mechanisms
- Vasculogenesis and Angiogenesis in Development
- Guidance of Vascular and Neuronal Network Formation
- The Angiogenic Switch in Tumorigenesis
- Pathophysiology and Clinical Implications of Vascular Endothelial Growth Factor
- Regulation of Angiogenesis and Vascular Homeostasis Through the Angiopoietin / Tie System
- Eph Receptors and Ephrins: Role in Vascular Development and Tumor Angiogenesis
- The Role of the Neuropilins and Their Associated Plexin Receptors in Tumor Angiogenesis and Tumor Progression
- Platelet-derived Growth Factor: Impact on Physiological and Tumor Angiogenesis
- Hypoxia and Tumour Angiogenesis
- Hypoxia and Angiogenesis in Glioblastomas
- Endogenous Inhibitors of Angiogenesis
- Thrombospondins and Angiogenesis
- Molecular and Cellular Aspects of Heparanase
- Vessel Maturation and Perivascular Cells
- Adhesion Molecules in the Vascular Cell Cross-Talk
- Homing and Differentiation of Endothelial Progenitor Cells
- Molecular Players in Lymphangiogenesis
- The Relationship Between Tumors and the Lymphatics: Consequences for Metastasis
- Inflammation and Angiogenesis: Innate Immune Cells as Modulators of Tumor Vascularization
- Arteriovenous Malformation in Mice and Men
- Animal Models and Preclinical Anti-Angiogenic Studies
- Vascular Endothelial Growth Factor Antibodies for Anti-Angiogenic Therapy
- Vascular Endothelial Growth Factor
- Vascular Endothelial Growth Factor Receptor Antibodies for Anti-Angiogenic Therapy
- Angiopoietin-2 Antagonists for Anti-Angiogenic Therapy
- Anti-Angiogenic Therapy with Thrombospondins
- The Use of Orthotopic Models to Validate Antivascular Therapies for Cancer
- Vascular Tumor Targeting
- Molecular Imaging of Targets and Therapeutics in Tumour Angiogenesis
- Imaging of Tumor Angiogenesis and Antiangiogenesis
- Visualization of Microcirculation and Anti-Angiogenic Tumor Therapy
- Cellular Actions of Angiogenesis Inhibitors on Blood Vessels
- Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment
- Metronomic Antiangiogenic Chemotherapy: Questions and Answers
- Anti-Angiogenic Tumor Therapy in Clinical Studies
- The Development of Avastin
- Clinical Development of Sorafenib (BAY 43–9006) VEGFR and RAF Inhibitor
- Clinical Development of the VEGFR Signalling Inhibitor AZD2171
- Clinical Development of Sunitinib Malate
- The EGF(R) and VEGF(R) Pathways as Combined Targets for Anti-Angiogenesis Trials in Cancer Therapy
- Imaging the Effect of Anti-Angiogenic Tumor Therapy in Clinical Studies
- Vandetanib (ZACTIMA™; ZD6474): Preclinical and Clinical Development
- Integrins: Targets for Anti-Angiogenic Therapy
- Thalidomide in Multiple Myeloma
- Surrogate Markers of Angiogenesis
- Vascular Disrupting Agents in Cancer Therapy.
